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Part I: Adsorbent resins are used in industrial fermentations to help boost the production 
of antibiotics.  The resins used here were utilized to help speed the drug discovery 
process by eliminating the time-consuming step of freeze-drying the fermentation 
extract.  This led to a shortened time span from receiving the fermentation to identifying 
the secondary metabolites via HPLC and LC/MS. 
Part II: Three new xanthones, 1-hydroxy-5-hydroxymethyl-6-methoxy-7-methyl-xanthone 
(1), 1-hydroxy-6-methoxy-7-methyl-xanthone (2), and 1-hydroxy-5,7-dimethyl-6-
methoxy-xanthone (3), were isolated from an unknown fungus, MSX 68425, from the 
Mycosynthetix library of filamentous fungi.  The compounds were discovered using 
bioactivity-directed fractionation, in pursuit of anticancer lead compounds.  The 
structures of these compounds were determined by spectroscopic and spectrometric 
techniques, in conjunction with comparisons to the literature.
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CHAPTER I 
 
INTRODUCTION 
 
 
The discovery and application of Penicillin has widely been hailed as the greatest 
medical discovery of the 20th century, helping to extend the life expectancy of humans by 
curing common, and once fatal, infections.  The discovery of additional antibiotics also 
ushered in the overuse of these compounds and modern medicine faces an unfortunate 
crisis against public health.  The rise of antibiotic resistance against some front line 
antimicrobial compounds is reaching a crisis level and as a result infections that had 
once become easily treatable, such as staph infection and tuberculosis, are once again 
public health hazards.  This problem has been exacerbated by the falling rate of 
discovery of novel antimicrobial classes in the laboratory.1,2 
The red soils of the Hashemite Kingdom of Jordan have been traditionally used 
as an anti-infective agent, being utilized to cure skin infections.  The traditional method 
was to create a paste using the soil and topically apply the paste daily onto the site of 
infection.  This traditional use triggered the investigation that determined the 
antimicrobial properties can be attributed to a host of bacteria, most notably 
Actinomycetes which are known to produce several antimicrobial compounds such as 
actinomycin.3  
Methicillin resistant Staphylococcus aureus (MRSA) is a common antibiotic 
resistant infection due to its prevalence in hospitals and on the human body.  The 
emergence of MRSA as a deadly infection has prompted the more common use of 
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alternative and more powerful antibiotics, such as vancomycin, that were once reserved 
only for the most dire of cases due to the potential side effects of the drugs.  The use of 
these “last line” antibiotics has led to the subsequent emergence of resistance against 
them as well.4   
Another emerging health hazard is drug resistant tuberculosis (XD-TB) and 
multiple drug resistant tuberculosis (XDR-TB).  This is a major problem in less 
developed countries with poor sanitation and little public health awareness.  Estimates 
put tuberculosis infections at 2 billion people worldwide with approximately 9 million 
deaths a year.  No new drugs for the treatment of tuberculosis have been 
commercialized since 1964.5 
There are several processes of how bacteria can gain antibiotic resistance.  
Mutation is the most common and well understood.  Another process is known as 
horizontal gene transfer, where a piece of genetic material that allows for resistance is 
transferred between a species or even across different species.6 
The production of antibiotics is achieved via two routes in the pharmaceutical 
industry: synthesis and fermentation.  Many of the front line antibiotics are synthesized in 
the laboratory.  Many other antibiotics, notably those that are difficult to synthesize, must 
be fermented by the microorganism that it was discovered in, or a genetically modified 
version.  Teicoplanin is used clinically to treat MRSA and can only be made 
economically by fermentation.7 A problem with this process is yield and extraction from 
the fermentation.  From this, a combination of resins and genetically modified 
microorganisms are typically used in industrial fermentations of antibiotics to increase 
yields and ease extraction of the desired product.8 
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The one use of adsorbent resins in fermentations is to prevent the negative 
feedback inhibition mechanism.9 This process is where the production of a certain 
compound will inhibit its further biosynthesis once a particular concentration has been 
attained.  The resin can also protect the metabolite from enzymatic conversion as the 
pores on the resin are usually too small for proteins to enter.10 This allows for an array of 
different resins to be developed and used for different types of bacterial fermentations.  
One particular drawback of adsorbent resins is that they are extracellular, and therefore 
can only interact with metabolites after they have been secreted from the cytoplasm.  A 
goal of the research conducted was to utilize the ability of the resin to adsorb secondary 
metabolites of the fermentation and subsequently extract the product in the laboratory, 
eliminating the time consuming steps of freeze drying and flash chromatography of the 
fermentation extract, thereby hastening the drug discovery process. 
The research presented here isolated three analogues of Actinomycin: D, X2, 
and P2 (order of elution) (figure 1).  Actinomycins are polypeptide compounds that 
exhibit potent antibacterial and anticancer properties.  They are produced by the 
bacterial family Actinomycete, most notably from the genus Streptomyces.  They display 
potent antimicrobial properties versus Gram positive bacteria, and a weaker activity 
against Gram negative bacteria and fungi.11 Their mechanism of action (MOA) is to 
inhibit DNA transcription by preventing the RNA Polymerase from binding and elongating 
on the DNA strand.12 Actinomycin D is the form currently used for medicinal purposes in 
chemotherapy and is generically known as dactinomycin.  It has lost its original use as 
an antibiotic because it can cause genetic damage due to its MOA and the relatively 
high concentration needed to obtain antibiotic efficacy.  Today it is mostly reserved for 
chemotherapy against Wilm’s Tumor (kidney cancer) and Rhabdomyosarcoma (skeletal 
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muscle cancer).  Actinomycin X2 and Actinomycin P2 are not utilized for medicinal 
purposes. 
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Figure 1: Structures of: a) Actinomycin D, b) Actinomycin X2, and c) Actinomycin P2 
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CHAPTER II 
 
METHODS 
 
 
A. Bacterial Fermentations  
The bacterium was identified as a Streptomyces sp. from the family Actinomycetes. 
The Bacterium was obtained from the red soils of the Hashemite Kingdom of Jordan.  
Fermentation was conducted in the laboratory of Dr. Joseph Falkinham III at Virginia 
Polytechnic University.  Fermentations were incubated at 30°C on a shaker for seven 
days in ¼ strength tryptic soy broth with 2% sucrose (v/v).  Bacterial culture purity was 
checked by streak plate at the end of the fermentation. 
B. XAD Resins  
The adsorbent resin was Amberlite XAD-7HP (figure 2), an acrylic ester that is 
moderately hydrophobic.  0.4 g of resin were used in fermentations that required resin.  
The resin was prewashed before application to the fermentation by a rinse in MeOH for 
15 min. 
C. Fermentation Conditions  
Three fermentation conditions were applied: 
1) Fermentation proceeded with resin for the entire time. 
2) Fermentation proceeded without resin; resin was added for 1h at the end. 
3) Fermentation proceeded without resin.
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D. Extraction  
The resin was recovered from the fermentation broth by centrifugation and filtration.  
The resin was stirred in a mixture of 1:1 CHCl3:MeOH for several hours to elute 
adsorbed metabolites from the resin.  The resin was filtered out using a vacuum filter 
system and a Whatman no. 1 filter.  Appropriate amounts of CHCl3 and H2O were added 
to obtain a 4:1:5 CHCl3:MeOH:H2O mixture.  This mixture was allowed to partition in a 
separatory funnel, and the lower organic layer was drawn off and evaporated to dryness.  
An aliquot of the crude extract was  tested in an antimicrobial assay (table 1) and the 
remainder of the fraction was analyzed via RP-HPLC for initial analytical testing.  RP-
HPLC-MS was utilized to determine the content of the sample.  The mass was used as a 
parameter in the Dictionary of Natural Products database for identification (DNP ver. 
20.1). 
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Figure 2: Amberlite XAD-7HP acrylic ester matrix.  
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E. Instrumentation  
RP-HPLC utilized a YMC ODS-A column (150 x 4.6 mm, 5 µm) at 1 mL/min with a 
gradient of 20 to 100% MeOH:H2O over 25 min.  HPLC system was a Varian Prostar 
equipped with Prostar 210 HPLC pumps and Prostar 335 photodiode array detector.  
Mass spectrometry analysis was performed on an Agilent 1100 HPLC system with an 
Agilent Triple-Quadrupole mass spectrometer.  The analysis on the RP-HPLC-MS was 
performed using a Prevail C18 column (50 mm x 2.3 mm, 3µm) at 1 mL/min with a 
gradient of 20 to 100% MeOH over 45 min. 
F.  Antimicrobial Assay  
Micrococcus luteus, Escherichia coli and Saccharomyces cerevisiae were each 
grown from a single colony in 0.1-strength brain heart infusion broth (Difco). Cultures 
were incubated for 18 h at 30°C. 13  The antimicrobial assay was conducted by broth 
microdilution in a 96-well plate containing M. luteus, E. coli, and S. cerevisae.  All 
samples were dissolved in DMSO.  Results were reported as the minimum concentration 
required for the inhibition of all growth of the organism.3 
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CHAPTER III 
 
RESULTS 
 
Organism 14-2-1 (Streptomyces sp.) yielded several secondary metabolites that were 
extracted from the adsorbent resin and, in case of fermentation condition three, the 
crude extract.  The crude extracts of each fermentation were sent for an antimicrobial 
assay against three orgranisms: Micrococcus luteus (Gram positive), Escherichia coli 
(Gram negative), and Saccharomyces cerevisae (yeast fungus).  The bioassay showed 
similar results for all three extracts (Table 1). 
Secondary metabolites were extracted from the resin using the 1:1 CHCl3:MeOH 
mixture and partitioned as described above.  The lower organic layer was drawn off and 
dried to attain a starting material weight.  This material was analyzed by RP-HPLC to 
determine the make-up of the sample (Figure 3). 
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Table 1:  MIC values for extracts of 14-2-1. All values reported as µg/mL. 
 
Grown 
with resin 
Grown without 
resin, resin added 
for 1hr. 
Grown without resin 
Micrococcus luteus 0.3 0.3 0.3 
Escherichia coli 110.4 58.3 74.3 
Saccharomyces cerevisae 176.7 181.7 152.1 
Fraction weight (mg) 8.4 11.5 13.5 
 
  
 
Figure 3: Three HPLC chromatograms from the three different growth conditions of 
organism 14-2-1 @245nm: a) Grown with resin for the entire fermentation, b) Grown 
without resin and resin added for 1 hour at the end of the fermentation, and c) Grown 
without resin, no resin added at end.
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After the gradient was established, the sample was analyzed by RP-HPLC-MS. 
(figure 4) The first HPLC peak at RT = 14.4 min displayed a m/z = 1255.27 [M + H]+, m/z 
= 1277.52 [M + Na]+, and m/z (z = 2) = 628.47 [M + H]+. (figure 5a) The second HPLC 
peak at RT = 15.59 min displayed a m/z = 1269.42 [M + H]+, m/z = 1291.48 [M + Na]+, 
and m/z (z = 2) = 635.92 [M + H]+. (figure 5b)  The third HPLC peak at RT = 15.73 min 
displayed a m/z [M + H]+ = 1283.46, m/z [M + Na]+ = 1305.47, and m/z (z = 2) = 635.53 
[M + H]+.(figure 5c)  The [M + H]+ mass data were entered into the Dictionary of Natural 
Products for reference.  The peak at RT = 14.4 min was shown to be Actinomycin D (m/z 
= 1254.63 [M + H]+) (figure 1a).  The peak at RT = 15.59 min was shown to be 
Actinomycin X2 (m/z = 1269.45 [M + H]+) (figure 1b).  The peak at RT = 15.73 min was 
shown to be Actinomycin P2 (m/z = 1283.46 [M + H]+) (figure 1c).  These data are 
consistent with the taxonomic data on organism 14-2-1, which is an actinomycete and 
known to produce actinomycins. 
Actinomycin D is the version of actinomycin used for comparison of other 
analogues, yielding a polypeptide sequence of L-Thr, D-Val, L-Pro, Sar, L-MeVal.  
Actinomycin X2 modifies the 43β position by oxidizing it to a ketone.  Actinomycin P2 
modifies the five member ring of the proline amino acid residue by including an extra 
carbon to make a six member ring. (figure 1) 
 
 
 
 
 
Figure 4: HPLC-MS Chromatogram 
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Figure 5: Mass spectrum: a) 01006-10-1 (RT = 14.5 min) positive mode, b) 01006-10-1 
(RT = 15.5 min) positive mode, and c) 01006-10-1 (RT = 16.6 min) positive mode 
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c) Actinomycin P2
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CHAPTER IV 
 
CONCLUSION 
 
 
The resin was able to sequester the bioactive compound from the fermentation 
broth.  While there was no apparent boost in production of the product for this particular 
organism, the recovery of the actinomycin was made easier by the presence of the resin.  
This eliminated a freeze drying step that was a 24 h process.  Some drawbacks to the 
use of adsorbent resins are the increase in cost of the fermentation.   
Extraction of the metabolite from the resin was achieved by using 1:1 
CHCl3:MeOH mixture.  The sequestration of three different forms of actinomycin was 
also an interesting effect of the experiment.  The presence of additional peaks in the 
LC/MS of the first growth condition allowed for additional study of metabolites that were 
present in the fermentation broth; these peaks were not present in the chromatograms of 
the other two growth conditions.  The masses of these peaks were entered in the DNP 
for analysis, and the results were inconclusive.   
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CHAPTER V 
 
INTRODUCTION 
 
 
In 2010, 1.5 million new cancers of cancer were reported in the USA, with an 
estimated 550,000 American deaths being attributed to cancer during the same year.14  
The leading cause of death among females was breast cancer, while males died most 
from lung cancer in the USA.15  This has prompted the need for a more diverse array of 
anticancer agents to be readily available. 
The discovery of antimicrobials from natural sources ushered in the discovery of 
chemotherapeutic agents from natural sources.  Vincristine (Catharanthus roseus),16 
camptothecin (Camptotheca acuminata),17 and taxol (Taxus brevifolia Nutt)18 were some 
of the first anticancer agents discovered from plants.19  Fungi are excellent sources of 
natural products, and are ubiquitous in nature.  The economic impact of fungal natural 
products is quite enormous, with about 22% of the known 12,000 antimicrobial 
compounds coming from filamentous fungi combining for a market value of $4.4 billion 
dollars.20 
The research conducted here focused on the secondary metabolites of 
filamentous fungi in pursuit of anticancer drug leads.  Filamentous fungi are a diverse 
group within the fungal kingdom, covering most of the higher evolved fungal species 
(non-yeast) and can be found all over the world.  Of course not all of the fungal 
metabolites are medicinally useful, as fungi also produce mycotoxins, which can cause 
19 
 
19 
 
serious illness or death.  The estimated number of filamentous fungi species is 
approximated to be 1.5 million, with only around 75,000 (5%) having been described in 
the literature.21  
The overall goal of the research was the isolation and structure elucidation of 
cytotoxic fungal metabolites.  The fungus (MSX 68425) was fermented at Mycosynthetix, 
Inc. in Hillisborough, NC.  MSX 68425 was selected for further study based on the 
bioactivity of the crude extract.  A human cancer cell line panel was used to test the 
crude extract of the organisms for anticancer activity.  The three cancer cell lines were:  
- MCF-7 human breast carcinoma, a medium growing cell line.22 
- H460 human large cell lung carcinoma, a fast growing cell line.23 
- SF268 human astrocytoma, slow growing cell line.24 
A percent survival rate of <20% at an extract concentration of 20 µg/mL is considered an 
active organism.  The overall objective of this cell line panel is to gain entry to the NCI 60 
cell line cancer panel with a novel, active anticancer compound. 
Dereplication is a method that helps to save time, money, and energy by making 
the drug discovery process more efficient while being thorough at the same time. This is 
done by screening out compounds that have already been discovered by comparing UV 
and High Resolution Mass Spectrometry (HRMS) data in databases.  An excellent 
database is The Dictionary of Natural Products (DNP), which comprises over 200,000 
naturally produced compounds in its library.  This source allows for the comparison of 
data from the various analytical techniques to a known library of compounds, such as 
unique UV spectra, NMR peaks, and the mass of the compound.   
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The research here yielded three fungal derived xanthones that displayed 
moderate cytotoxicity in the human cancer cell panel.  All three are new xanthones, 
never having been discovered from a natural source before.   
A xanthone (C13H8O2) is a three membered ring system consisting of two 
benzene rings, one derived from acetate unites (ring A) and one derived from shikimic 
acid (ring B), joined by a carbonyl and an oxygen to form a central six member ring 
between the two benzenes that lies flat in the plane, a characteristic of many anticancer 
drug compounds.25 (figure 6).   
Xanthones are found in many angiosperms (flowering and fruiting plants) as well 
as fungi and lichens. (Cardona 1990) A search in the Dictionary of Natural Products 
yielded 900 xanthones, with ~10% of the 900 assigned xanthones originating from fungi 
and the remainder from higher plants. 
Xanthones show a wide spectrum of activity and have been evaluated for 
anticancer, anti-inflammatory,26 antibiotic,27 antifungal,28 and antioxidant29 properties.  
The furanoxanthone psorospermin (figure 7), isolated from the plant Psorospermum 
febrifugum Spach, has been identified to have a novel mechanism of action for an 
antiproliferative agent by being an irreversible DNA topoisomerase II inhibitor.  
Psorospermin is the target of ongoing DNA alkylation studies, as well as being in 
preclinical development as anticancer agent.30 
Psorospermin has garnered more interest in xanthones as chemotherapeutic agents, 
due to its unique interaction with DNA in the cell.  Xanthones interact exclusively with 
DNA or DNA-protein complexes in the cell, causing DNA breakage or protein binding 
inhibition, which both lead to cancer cell death.  The ability of xanthones to intercalate 
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with DNA base pairs, believed to be due to the planar ring system, suggests promise as 
anticancer drug leads.  This has led many scientists to push for discovery of new 
xanthones or synthesis of new xanthones for drug discovery.31 
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Figure 6: Xanthone structural backbone. Ring A is polyketide derived, Ring B is from 
shikimic acid. 
 
O
O OH
OH
OH
OH
OOH
AB
 
 
Figure 7: Psorospermin, isolated from Psorospermum febrifugum.31 
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CHAPTER VI 
 
METHODS 
 
 
A. Fermentation 
The fungal isolate MSX 68425 was obtained from the Mycosynthetix, Inc. library 
of filamentous fungi (Hillsborough, NC).  Taxonomic studies are ongoing. 
The culture was stored on a malt extract slant and transferred periodically. A 
fresh culture was grown on a similar slant, and a piece was transferred to a medium 
containing 2% soy peptone, 2% dextrose, and 1% yeast extract (YESD media). 
Following incubation (7 d) at 22 °C with agitation, the culture was used to inoculate 50 
mL of a rice medium, prepared using rice to which was added a vitamin solution and 
twice the volume of rice with H2O, in a 250 mL Erlenmeyer flask. This was incubated at 
22°C until the culture showed good growth (approximat ely 14 d). 
B. Instrumentation 
NMR instrumentation was a JEOL ECA-500, operating at 500 MHz for 1H and 
125 MHz for 13C, with JEOL Delta software for analysis.  All NMR experiments were in 
CDCl3.  Compounds 1 and 3 were analyzed using a JEOL 5mm tunable PFG NM-
50TH5AT/FG2 probe, while compound 2 was analyzed using a Protasis inverse carbon 
gradient capillary probe.  HRMS was performed on a Thermo-Scientific LTQ-Orbitrap 
system with an ESI source and Waters Acquity UPLC front end.  The operating
24 
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parameters for the source were 4.5 kV spray voltage, 1000 V tube lens voltage, a 
capillary temperature of 270 C, and a sheath gas volume of 15 arb.  UPLC conditions 
were 20:80  100% ACN:H2O over 7 min at 0.6 mL/min on a Prevail C18 column (50 
mm x 2.1 mm x 3 µm).  HRMS data was collected with Xcalibur software.  Normal Phase 
Flash Chromatography was conducted on a Teledyne-Isco CombiFlash Rf system using 
a RediSep Rf Si-gel Gold column (Lincoln, NE, USA).  HPLC was executed on Varian 
Prostar HPLC Systems (Walnut Creek, CA, USA) equipped with Prostar 210 HPLC 
pumps and Prostar 335 photodiode array detector.  HPLC data were collected and 
analyzed with Galaxie Chromatography Workstation Software version 1.9.3.2.  Analytical 
HPLC was performed with a Gemini-NX column (150 x 4.6 mm, 5 µm) at 1 mL/min, 
preparative HPLC was performed with a Gemini-NX column (250 x 21.2 mm, 5 µm) at 15 
mL/min, and semi-preparative HPLC was performed with a Gemini-NX column (250 x 
10.0 mm, 5 µm) at 4 mL/min.  All three columns were manufactured by Phenomenex 
(Torrence, CA, USA).   
C. Bioactivity-Directed Fractionation   
The fungal sample was fermented and a 1:1 CHCl3:MeOH mixture was added 
and stirred overnight.  The mixture was partitioned in a 4:1:5 CHCl3:MeOH:H2O mixture. 
The organic layer was drawn off and dried to obtain a crude extract.  This crude extract 
was tested in the cancer bioassay for activity.  A positive result (<20% survival at 20 
µg/mL) in the bioassay of the crude extract points to a further investigation of the 
organism.   
The crude extract was fractionated by an ISCO normal phase flash 
chromatography system. (Figure 8) This material was fractionated at 40 mL/min on a 
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RediSep Rf Gold silica gel column (4 g), first with 100% hexanes for 0.7 column volumes 
(CV) followed by a gradient of 100% hexanes to 100% CHCl3 over 8.9 CV. The elution 
continued with 100% CHCl3 for 7.4 CV, then with a gradient of MeOH in CHCl3 (0-2% 
over 9.7 CV, then 2-5% over 5.2 CV, then 5-10% over 5.2 CV, then 10-20% over 3.7 CV, 
then 20-100% over 2.2 CV. MeOH (100%) was finally held for a further 6.7 CV). 
Fractions were collected every 24.75 mL.  Five pools were generated by combining 
fractions, and these were tested for cytotoxicity.  Pool 2 (167.4 mg) was cytotoxic and 
subjected to preparatory RP-HPLC, using a gradient of at 15 mL/min 50-100% CH3CN in 
H2O over 30 min;  Elution times and amount isolated were 1: 11 min (10.2 mg), 2: 18.5 
min (5.8 mg), 3: 21 min (7.0 mg).  Compounds 1 and 3 were >95% pure (via UPLC) after 
the first round of prep-HPLC, while Compound 2 was 80% pure and required two 
additional rounds of purification to yield 0.6 mg of pure compound.
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Figure 8: ISCO flash chromatogram of organic extract from organism MSX-68425. Blue 
line is the gradient. Orange line is all wavelength UV.  Green line is ELS detection. 
2
6
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Table 2: Sample ID, bioassay data, and weight obtained for flash chromatography from 
MSX 68425. All data is percent survival of cell line.  (sm = starting material prior to 
fractionation) 
 
Sample ID Conc. MCF-7wtk H460 SF268 Amount (mg) 
01007-33-sm 
 
20 µg/mL 
2 µg/mL 
31.7 
98.9 
13.7 
91.6 
45.5 
97.5 
 
01007-33-1 
 
20 µg/mL 
2 µg/mL 
105.3 
102.4 
101.0 
106.1 
108.3 
105.1 
2.1 
01007-33-2 
 
20 µg/mL 
2 µg/mL 
30.4 
100.2 
11.5 
93.7 
44.3 
94.8 
167.4 
01007-33-3 
 
20 µg/mL 
2 µg/mL 
49.2 
100.5 
42.6 
99.9 
63.1 
108.6 
26.6 
01007-33-4 
 
20 µg/mL 
2 µg/mL 
69.2 
102.0 
84.9 
109.3 
94.4 
113.7 
30.1 
01007-33-5 
 
20 µg/mL 
2 µg/mL 
90.4 
100.1 
82.0 
105.5 
73.6 
108.7 
22.9 
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D. Purification and Analysis  
Active fractions were analyzed via RP-HPLC (figure 9) for establishment  of a 
gradient for use with preparative HPLC.  The fractions are then purified (>95%) by 
preparative-HPLC (figure 10) and pooled based on the UV chromatogram and PDA 
profiles to isolate the compounds.  Purified fractions are submitted for further bioassay 
testing to verify activity in the fraction (table 3) and then analyzed by Nuclear Magnetic 
Resonance Spectroscopy (NMR) and High Resolution Mass Spectrometry (HRMS) for 
chemical structure elucidation. 
 
Figure 9: Analytical HPLC chromatogram of 01007-33-2 @230 nm. 
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Figure 10: a) Preparative HPLC of 01007-33-2 (vertical black bars represent fractions) 
and b) pooling based on chromatogram 
a) 
 
b) 
Sample ID 
Pooled 
Fractions 
Wt. (mg) 
01007-150-1 14-24 10.2 
01007-150-2 27-31 5.0 
01007-150-3 32-37 5.8 
01007-150-4 39-43 7.0 
01007-150-5 44-49 11.0 
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Table 3: Bioassay data for fractions of 01007-33-2 (renamed 01007-150). Numbers are 
%  survival. A survival rate of <20% for the 20 µg/mL concentration is considered active. 
 
Sample ID Conc. MCF-7 H460 SF268 
01007-150-sm 
20 µg/mL 
2 µg/mL 
41.9 
84.6 
30.6 
115.3 
31.8 
95.1 
01007-150-1 
20 µg/mL 
2 µg/mL 
48.7 
93.3 
80.9 
103.6 
89.6 
91.6 
01007-150-2 
20 µg/mL 
2 µg/mL 
39.6 
102.8 
14.1 
108.2 
37.6 
97.8 
01007-150-3 
20 µg/mL 
2 µg/mL 
30.3 
117.3 
7.1 
98.7 
23.0 
92.6 
01007-150-4 
20 µg/mL 
2 µg/mL 
10.8 
26.6 
0.7 
8.5 
10.2 
33.1 
01007-150-5 
20 µg/mL 
2 µg/mL 
19.7 
71.0 
8.1 
69.2 
24.8 
71.8 
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E. Human Cancer Cell Panel   
The human cancer cell panel growth and testing were conducted at the department 
of pharmaceutical sciences at North Carolina Central University in Durham, NC in the 
laboratory of Dr. David J. Kroll.  Initial crude extract, fractionations, and prep-HPLC 
bioassays were at concentrations of 20 µg/mL and 2 µg/mL.  EC50 values were obtained 
by serially diluting the concentration (µM) in half log steps.  All samples were dissolved 
in DMSO and the final concentration was ≤ 0.5%. 
The human cancer cell panel consisted of MCF-7 human breast carcinoma (Barbara 
A. Karmanos Cancer Center, Detroit, MI), NCI-H460 human non-small cell lung 
carcinoma (American Type Culture Collection, Manassas, VA), and SF-268 human 
astrocytoma (NCI Developmental Therapeutics Program, Frederick, MD).  All cell lines 
were adapted and maintained RPMI-1640 medium supplemented with fetal bovine 
serum at 10% (v/v), 100 U/mL penicillin G, and 100 µg/mL streptomycin sulfate.  The 
atmosphere was maintained at 5% CO2 and 37 C.  Cells were used in the logarithmic 
growth phase. Cell suspensions were prepared at densities of 3,000 (MCF-7), 1,500 
(H460), and 10,000 (SF-268) cells/50 µL of medium.32 The assay was monitored at the 
UV maximum of 562 nm.12  
32 
 
 
 
CHAPTER VII 
 
RESULTS 
 
 
The crude extract of the small scale fermentation of MSX 68425 showed moderate 
activity in the human cancer cell panel as evidenced by ~10% cell survival of H460 cells 
when tested at 20 µg/mL.  The crude extract was fractionated via normal phase flash 
chromatography, and the resultant pools were tested in the human cancer cell line 
panel.  The second pool showed activity that was slightly more potent than the crude 
extract and was then subjected to preparatory scale HPLC for purification of the 
compounds.  The numbering of the isolated compounds (1 – 3) relates to their order of 
elution in RP-HPLC purification of fraction 01007-33-2.   
A. 01007-150-1 (Compound 1) 
01007-150-1 (figure 11) was isolated after one round of prep-HPLC with a purity 
>95%, verified via UPLC (Figure 12).  A comparison of the UV data (λmax 233, 259, 293, 
and 374 nm) showed that the three isolated compounds were closely related, and this 
was confirmed by 1H NMR data, as the chemical shifts and splitting in the aromatic 
region (δH 6.7-7.6) were highly similar (see table 4).  Dereplication of the compounds 
was attempted by inputting the HRMS and UV data (+- 10nm) into the Dictionary of 
Natural Products database (DNP ver. 20.1); no matches were found.   
Compound 1 was a yellow crystalline solid, which is characteristic of xanthones.  
The HRMS data was m/z = 287.09070 [M + H]+ with a second mass peak at m/z = 
269.08011 [(M – H2O) + H]
+ , denoting a loss of H2O (m/z = 18).  Using the HRMS data, 
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a chemical formula of C16H14O5 was calculated, corresponding to an Index of Hydrogen 
Deficiency (IHD) of 10.  The 13C NMR (figure 14) data showed twelve peaks in the 
aromatic region, with eight of those being quaternary carbons, and a peak at δC 184 
denoting a ketone.  These results were combined with 1H NMR data (figure 13), which 
showed four aromatic protons H-2 (δH 6.8), H-3 (δH 7.6), H-4 (δH 6.9), and H-8 (δH 7.3), 
helping to confirm that the backbone of 1 was a tetra substituted xanthone.  The 
substituents were determined from the 1H NMR data as phenol (δH 12.6), hydroxymethyl 
[δH 5.0 (CH2) and δH 4.5 (-OH)], methoxy (δH 3.8), and methyl (δH 2.5) groups.   
The positions of the substituents and aromatic protons were determined by 2D-
NMR.  The three 2D-NMR experiments utilized here were: COSY (Correlation 
spectroscopy, 1H-1H correlations of adjacent protons), HSQC-edited (Heteronuclear 
single quantum coherence, direct 1H-13C connectivity phase edited giving results similar 
to DEPT-135 13C NMR), and HMBC (Heteronuclear multiple bond correlation, long range 
(2-4 bonds, 3 typically) 1H-13C correlations). Only one spin system was observed in the 
COSY spectrum (figure 15) for the correlations between H-2 (δH 6.8), H-3 (δH 7.6), and 
H-4 (δH 6.9).  In the HSQC-edited NMR experiment (figure 16), the aromatic protons at 
δH 7.6 (H-3), δH 6.9 (H-2), and δH 6.8 (H-4) correlated to the carbon signals at δC 137.0 
(C-3), δC  110.6 (C-2), and δC 106.7 (C-4), respectively.  In the HMBC experiment (figure 
17), the proton at δH 7.3 (H-8) correlated to the methyl group at δC 17.5 (C-12), the 
carbon at δC 153.8 (C-6), and the carbonyl at δC 184.5 (C-9).  The methoxy proton at δH 
3.8 (H-11) showed a correlation in the HMBC spectrum to the quaternary carbon at C-6.  
The hydroxymethyl –CH2- proton at δh 5.0 (H-10) correlated to the quaternary carbon at 
C-6 as well, denoting its position on C-5.  The phenolic proton signal at δH 12.6 was 
determined to be on C-1 by the HMBC correlations to the carbon at δC 110.6 (C-2) and 
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δC 109.2 (C-9a).  Compound 1 was determined to be a new xanthone, and was assigned 
the systematic name 1-hydroxy-5-(hydroxymethyl)-6-methoxy-7-methyl-xanthone. 
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Figure 11: Proposed structure of compound 1 (01007-150-1) 
9a
4a
1
4
2
3
7
6
8
5
CH3
12
O
O O
CH3
11
OH
10
OH
8a
4b
9
 
 
Figure 12: UPLC @ 235 nm of compound 1 (01007-150-1) showing >95% purity 
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Figure 13: 1H NMR of Compound 1 (CDCl3) and expansion of aromatic region (δH 6.5-
7.0) (inset) 
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Figure 14:  13C NMR data of compound 1 
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Figure 15: COSY NMR data of Compound 1 
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Figure 16: HSQC-edited NMR data of Compound 1 
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Figure 17: HMBC NMR data of Compound 1 
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Table 4:  NMR data table for compounds (1 – 3).  13C data for 2 is inferred from HSQC 
and HMBC spectra. 
 
Position Compound 1 Compound 2 Compound 3 
 δH Mult (J in 
Hz)  
δC δH Mult (J in 
Hz) 
δC δH Mult (J in Hz) δC 
1  161.9  162.2  162.2 
2 6.9   d    8 106.7 6.8   d   8 108.0 6.8   d   8 106.3 
3 7.6   t     8 137.0 7.6   t    8 136.4 7.5   t    8 136.1 
4 6.8   d    8 110.6 6.9   d   8 110.4 6.7   d   8 110.1 
4a  155.7  156.7  155.7 
4b  154.1  151.5  153.4 
5  134.1 7.5   s 103.0  133.1 
6  153.8  155.4  153.9 
7  142.6  138.7  140.8 
8 7.3   s 119.7 7.3   s 120.0 7.1   s 117.2 
8a  118.1  119.5  118.0 
9a  109.2  109.0  109.4 
9  184.5  182.6  184.6 
10 5.0   s 56.9   2.8   s 14.7 
11 3.8   s 62.8 3.9   s 56.0 3.7   s 60.4 
12 2.5   s 17.5 2.4   s 17.8 2.4   s 17.3 
       
1-OH 12.6   s  12.8   s  13.0   s  
10-OH 4.5   bs      
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B. 01007-150-3 (Compound 2) 
Compound 2 (figure 18) was purified to >95% purity by several rounds of prep-HPLC.  
The UV (λmax 235, 269, 290, and 380 nm) and mass spectrometry data of 2 were found 
to be similar to 1.  The key difference from the latter was a molecular ion (m/z = 
257.08026 [M + H]+), corresponding to a molecular formula of C15H13O4 and an IHD of 
10, that was 30 mass units different than 1, suggesting the absence of a –CH2-O- 
moiety.   
Due to a paucity of sample this compound was analyzed utilizing a capNMR probe, and 
the 13C assignments were extrapolated from the HSQC and HMBC experiments. The 
alteration of the substituents was verified by the 1H capNMR data (figure 19), showing 
the absence of the hydroxymethyl group and the presence of an additional proton in the 
aromatic region (H-5 δH 7.5).  The signals for the phenol at C-1 (H-1 δH 12.7), methoxy at 
C-6 (H-11 δH 3.9), and methyl at C-7 (H-12 δH 2.4) were present in the 
1H NMR spectra, 
helping to confirm the similarity of compounds 1 and 2.  The HSQC NMR data (figure 21) 
showed the additional 1H-13C correlation of the proton at postion 5.  HMBC correlations 
(figure 22) were also present from the proton at H-5 (δH 7.5) to the carbons at C-6 (δC 
155.4), C-7 (δC 138.7), and C-4b (δC 151.4).  Compound 2 was determined to be a new 
xanthone, and was assigned the systematic name 1-hydroxy-6-methoxy-7-methyl-
xanthone. 
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Figure 18: Proposed structure of 01007-150-3 Compound 2 
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Figure 19: UPLC of Compound 2 @235 nm showing >95% purity. 
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Figure 20: 1H capNMR spectrum for Compound 2 (CDCl3) and expansion of aromatic 
region (δH 6.5-8.0) (inset) 
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Figure 21: HSQC-edited spectrum of compound 2 (CDCl3, CapNMR) 
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Figure 22: HMBC spectrum of compound 2 (CDCl3, CapNMR) 
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C. 01007-150-4 (Compound 3) 
Compound 3 (figure 23) was purified to >95% (figure 24) by a single round of prep-
HPLC.   The UV (λmax 234, 256, 287, and 369 nm) and mass spec data showed that 3 
was similar to 1.    The mass spec data (m/z = 271.09586 [M + H]+) corresponded to a 
chemical formula of C16H14O4 and an IHD of 10.  Comparison of the HRMS data 
between 1 and 3 showed the difference of mass to equal that of an oxygen atom.  This 
was confirmed through the 1H NMR data (figure 25) that showed the absence of the -
CH2-O- moiety, and the presence of an additional singlet in the upfield region δH 2.8 (H-
10) of the spectrum.  The 13C data (figure 26) confirmed the presence of an additional 
methyl group at δC 14.6 (C-10).  The proton signals for the phenol at C-1 (H-1 δH 13.0), 
methoxy group at C-6 (H-11 δH 3.7), and methyl group at C-7 (H-12 δH 2.4) were present 
in the 1H NMR spectrum.  The additional upfield proton signal was determined to be a 
methyl group at the C-5 position.  2D NMR was utilized to confirm the positions of the 
methyl groups and assignment of the 13C and 1H NMR signals.  The HSQC-edited 
experiment (figure 27) showed the correlation of the methyl group attached to position C-
5 of the xanthone (δH-10/δC-10 = 2.8/14.7) and the C-7 methyl group (δH-12/δC-12 = 
2.4/17.3)).  In the HMBC experiment (figure 28), the methyl proton at H-10 (δH 2.8) 
correlated to C-6 (δC 153.9) and C-4b (δC 153.4) confirming its position at C-5.  
Compound 3 was determined to be a new xanthone and was assigned the systematic 
name 1-hydroxy-5,7-dimethyl-6-methoxy-xanthone. 
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Figure 23: Proposed structure of 01007-150-4 Compound 3 
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Figure 24: UPLC of Compound 3 (01007-150-4) showing >95% purity. 
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Figure 25: 1H NMR data for Compound 3 (CDCl3) and expansion of aromatic region (δH 
6.5-8.0) (inset) 
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Figure 26: 13C NMR of Compound 3 in CDCl3 (01007-150-4) 
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Figure 27: HSQC-edited spectrum of Compound 3 (01007-150-4) 
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Figure 28: HMBC spectrum of Compound 3 (01007-150-4) 
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D. EC50 
The EC50 of all three compounds was evaluated.  The assay was performed at North 
Carolina Central University.  The assay was performed as a serial dilution to obtain 50% 
growth inhibition of the cancer cell line.  This assay was performed with a positive control 
of camptothecin, a known and commercially used chemotherapeutic agent.  The results 
are reported in µM. 
 
Table 5: EC50 bioassay data.  All results in µM. 
 
EC50 (µM) 
 MCF-7 H460 SF268 
Camptothecin 0.15 0.01 0.07 
Compound 1 100 58.3 100 
Compound 2 100 100 100 
Compound 3 100 59.6 100 
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CHAPTER VIII 
 
CONCLUSION 
 
 
Using the method of bioactivity-directed fractionation, three new xanthones were isolated 
and their structures elucidated via a suite of spectroscopic and spectrometric 
techniques.  The xanthone backbone has been well described in the literature due to its 
prevalence in nature, but the continuing discovery of new xanthones points to the 
diversity of the substituents found on the xanthone backbone.  The fungus (MSX 68425) 
biosynthesized xanthones (1 - 3) that were altered only at the C-5 position, which had an 
effect on the cytotoxicity of the compounds with the methyl group or hydroxymethyl at C-
5 (compounds 1 and 3) being more potent than the non-substituted compound at the 
same position (compound 2).  
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